---
title: "Ascendis Pharma A/S reports results for the quarter ended December 31 - Earnings Summary"
date: "2025-02-13 10:55:10"
summary: "Ascendis Pharma A/S reported a quarterly adjusted loss of 64 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of €-1.54. The mean expectation of fourteen analysts for the quarter was for a loss of 96 cents per..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Ascendis Pharma A/S reported a quarterly adjusted loss of 64 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of €-1.54. The mean expectation of fourteen analysts for the quarter was for a loss of 96 cents per share. Wall Street expected results to range from €-1.78 to 23 cents per share.
* Revenue rose 26.3% to €173.92 million from a year ago; analysts expected €119.71 million.
* Ascendis Pharma A/S's reported EPS for the quarter was a loss of 64 cents​.
* The company reported a quarterly loss of €38.47 million.
* Ascendis Pharma A/S shares had fallen by 13.2% this quarter.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 33.9% in the last three months.​
* In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Ascendis Pharma A/S is $196.00

This summary was machine generated from LSEG data February 13 at 02:55 a.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact [RefinitivNewsSupport@thomsonreuters.com](http://mailto:RefinitivNewsSupport@thomsonreuters.com))

| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| --- | --- | --- | --- |
| Dec. 31 2024 | -0.96 | -0.64 | Beat |
| Sep. 30 2024 | -1.74 | -1.72 | Beat |
| Jun. 30 2024 | -1.38 | -1.91 | Missed |
| Mar. 31 2024 | -1.50 | -2.30 | Missed |

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3P404T:0-ascendis-pharma-a-s-reports-results-for-the-quarter-ended-december-31-earnings-summary/)
